Evidence map›Paper›PMID 42437857›Full record

ArticleEJNMMI reports2026

Quantitative bone SPECT/CT-derived tumor burden as a prognostic biomarker in metastatic castration-resistant prostate cancer treated with Ra-223.

Yoshimitsu Fukushima, Go Kimura, Jun Akatsuka, Yoshimitsu Honda, Yujiro Nakaoka, Hiromitsu Hayashi, Shinichiro Kumita

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yoshimitsu FukushimaDepartment of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. fuku@nms.ac.jp.ORCID http://orcid.org/0000-0001-6224-4914
Go KimuraDepartment of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Jun AkatsukaDepartment of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Yoshimitsu HondaDepartment of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Yujiro NakaokaDepartment of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Hiromitsu HayashiDepartment of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Shinichiro KumitaDepartment of Radiology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetastatic castration-resistant prostate cancer (mCRPC) is bone-predominant, requiring objective imaging biomarkers to guide Ra-223 therapy. We evaluated overall metabolic bone volume (OMBV) and overall total bone uptake (OTBU) from bone SPECT/CT as prognostic markers in mCRPC patients treated with Ra-223.

methodsThirty mCRPC patients underwent pre-treatment planar and SPECT/CT bone scintigraphy, with OMBV and OTBU derived using GI-BONE software. Overall survival (OS) was the primary endpoint; progression-free survival (PFS) and time to symptomatic skeletal event (TTSE) were secondary. Receiver operating characteristic analysis (Youden index) defined cut-offs for OS and TTSE independently. Treatment response was classified by composite changes in OMBV, OTBU, and bone scan index. OS, OMBV, and OTBU were analyzed by univariate Cox regression as continuous and dichotomized variables.

resultsBaseline skeletal burden was substantial (median OMBV 1,191.21 cm

conclusionsOMBV and OTBU from bone SPECT/CT may provide useful prognostic information in mCRPC patients undergoing Ra-223 therapy, offering objective quantification of skeletal tumor burden using widely available technology. Further validation in larger cohorts is warranted.

Indexed as

Bone metastasesBone SPECT/CTCastration-resistant prostate cancerPrognostic biomarkerRa-223

Identifiers

PMID42437857
PMCPMC13357462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.